Abstract
The development of resistance to chemotherapeutic agents is still a major cause of treatment failure in cancer patients. The mechanisms by which drug resistance develops are poorly understood. Cyclophosphamide (CP) is widely used in the treatment of different hematological malignancies and in a variety of solid tumors. Furthermore, CP is incorporated in many conditioning regimens prior to bone marrow transplantation. Its in vitro active metabolite 4-hydroperoxycyclophosphamide is frequently used for purging purposes in case of autologous bone marrow transplantation for acute leukemia [1]. Obviously, given these clinical applications, studies on the mechanism(s) of CP resistance are highly relevant.
These investigations were supported by the Dutch Cancer Society, the Josephine Nefkens Foundation, the Nijbakker-Morra Foundation, and ASTA-Werke A.G., Bielefeld, FRG.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Yeager AM, et al. (1986) Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315: 141–147
Martens ACM, van Bekkum DW, Hagenbeek A (1990) The BN acute myelocytic leukemia (BNML) (A rat model for studying human acute myelocytic leukemia ( AML)). Leukemia 4: 241–257
Martens ACM, de Groot CJ, Hagenbeek A (1991) Development and characterization of a cyclophosphamide resistant variant of the BNML rat medel for acute myelocytic leukemia (AML). Eur J Cancer (recently published =) Eur. J. Cancer 27: 161–166
Brock N (1989) Oxazaphosphorines cytostatics: past-present-future. Seventh Cain Memorial Award Lecture. Cancer Res 49: 1–7
Hilton J (1984) Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 44: 5156–5160
Koelling TM, et al. (1990) Development and characterization of a cyclophosphamideresistant subline of acute myeloid leukemia in the Lewis x Brown Norway hybrid rat. Blood 76: 1209–1213
Sladek NE, Landkamer GJ (1985) Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Cancer Res 45: 1549–1555
McGown AT, Fox BW (1986) A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in aYoshida cell line in vitro. Cancer Chemother Pharmacol 17: 223–226
Suzukake K, Petro BJ, Vistica DT (1982) Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem Pharmacol 31: 121–124
Arkesteijn GJA, et al. (1987) Bivariate flow karyotyping of acute myelocytic leukemia in the BNML rat model. Cytometry 8: 618–624
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
de Groot, C.J., Martens, A.C.M., Hagenbeek, A. (1992). On the Role of Aldehyde Dehydrogenase in a Cyclophosphamide-Resistant Variant of Brown Norway Rat Acute Myelocytic Leukemia. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-76591-9_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53949-0
Online ISBN: 978-3-642-76591-9
eBook Packages: Springer Book Archive